What is TOKU-E?
TOKU-E specializes in producing high-purity antimicrobials and fine chemicals essential for various life science applications, including gene selection, cell culture, and diagnostics. The company distinguishes itself by supplying competitively priced products to both retail and chemical supply markets, emphasizing excellent customer service and deep product knowledge. TOKU-E also offers custom synthesis services, catering to specific client needs for both existing and novel chemical compounds, demonstrating a commitment to innovation and client-centric solutions within the biopharmaceutical and diagnostic industries.
How much funding has TOKU-E raised?
TOKU-E has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in TOKU-E
PPP
Public-Private Partnership
What's next for TOKU-E?
With the recent influx of strategic capital, TOKU-E is poised for accelerated expansion and enhanced product development. The company's focus on custom synthesis and its ability to meet diverse packaging and shipping requirements position it favorably for capturing greater market share. This late-stage funding is expected to fuel advancements in its manufacturing capabilities and broaden its reach within the global biotechnology research community, reinforcing its role as a key supplier of critical research materials.
See full TOKU-E company page
